References
- Sierra C, de la Sierra A. Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Curr Opin Nephrol Hypertens 2005;14:435-41. https://doi.org/10.1097/01.mnh.0000174397.59100.89
- Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536.
- Jung AD, Kim W, Park SH, et al. The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension. Korean Circ J 2009;39:180-4. https://doi.org/10.4070/kcj.2009.39.5.180
- Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53. https://doi.org/10.1056/NEJM200001203420301
- Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003. https://doi.org/10.1016/S0140-6736(02)08089-3
- Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity. Hypertension 2004;43:993-1002. https://doi.org/10.1161/01.HYP.0000123072.34629.57
- Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-7. https://doi.org/10.1161/01.CIR.0000127955.36250.65
- Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001;103:448-54. https://doi.org/10.1161/01.CIR.103.3.448
- Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003;42:905-10. https://doi.org/10.1016/S0735-1097(03)00846-5
- Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110:1103-7. https://doi.org/10.1161/01.CIR.0000140265.21608.8E
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9. https://doi.org/10.1007/BF00280883
- Hwang WM, Bae JH, Kim KY, Synn YC. Impacts of atherosclerotic coronary risk factors on atherosclerotic surrogates in patients with coronary artery disease. Korean Circ J 2005;35:131-9.
- Safar ME, Smulyan H. Measurements of arterial stiffness: are they ready for clinical use? Current Cardiovascular Risk Reports 2008;2:268-73, doi: 10.1007/s12170-008-0050-z.
- Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65.
- Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8. https://doi.org/10.1016/0002-9149(86)90771-X
- Kim KI, Kim Y, Kim HJ, et al. Current status and characteristics of hypertension treatment by primary physicians in Korea: data from Korean Epidemiology Study on Hypertension (KEY study). Am J Hypertens 2008;21:884-9. https://doi.org/10.1038/ajh.2008.191
- Neutel JM. Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy. Curr Med Res Opin 2010;26:213-22. https://doi.org/10.1185/03007990903444434
- Smith DH, Cramer MJ, Neutel JM, Hettiarachchi R, Koval S. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003;8:111-7. https://doi.org/10.1097/00126097-200306000-00004
- Lacourciere Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004;9:203-10. https://doi.org/10.1097/00126097-200408000-00005
- Song HG, Kim EJ, Seo HS, et al. Relative contributions of different cardiovascular risk factors to significant arterial stiffness. Int J Cardiol 2010;139:263-8. https://doi.org/10.1016/j.ijcard.2008.10.032
- Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006;19:214-9. https://doi.org/10.1016/j.amjhyper.2005.08.007
- Karalliedde J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008;51:1617-23. https://doi.org/10.1161/HYPERTENSIONAHA.108.111674
- Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? J Hypertens 2005;23:551-6. https://doi.org/10.1097/01.hjh.0000160211.56103.48
- Yamamoto K, Mano T, Yoshida J, et al. ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure. J Hypertens 2005;23:393-400. https://doi.org/10.1097/00004872-200502000-00022
- Brooks WW, Bing OH, Robinson KG, Slawsky MT, Chaletsky DM, Conrad CH. Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 1997;96: 4002-10. https://doi.org/10.1161/01.CIR.96.11.4002
- Ciulla MM, Paliotti R, Esposito A, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation 2004;110:552-7. https://doi.org/10.1161/01.CIR.0000137118.47943.5C
- Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63. https://doi.org/10.1016/j.echo.2005.10.005
Cited by
- A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction vol.36, pp.7, 2011, https://doi.org/10.1038/hr.2012.233
- The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO) vol.10, pp.1, 2013, https://doi.org/10.1177/1479164112444640
- Efficacy of losartan and carvedilol on central hemodynamics in hypertensives: a prospective, randomized, open, blinded end point, multicenter study vol.37, pp.1, 2011, https://doi.org/10.1038/hr.2013.112
- A meta-analysis of randomized controlled trials of telmisartan for flow-mediated dilatation vol.37, pp.9, 2011, https://doi.org/10.1038/hr.2014.81